Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

MLA

Ibrahim Petekkaya, et al. “Trastuzumab Emtansine (T-DM1) for HER2-Positive Breast Cancer.” Current Medical Research and Opinion, vol. 29, no. 4, Feb. 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e136c770d297110b9612879f80ad3b37&authtype=sso&custid=ns315887.

APA

Ibrahim Petekkaya, Taner Babacan, Baris Boyraz, Mehmet Ali Nahit Sendur, Sercan Aksoy, Emir Charles Roach, Kadri Altundag, & Muhammet Cemal Kizilarslanoglu. (2013). Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Current Medical Research and Opinion, 29(4).

Chicago

Ibrahim Petekkaya, Taner Babacan, Baris Boyraz, Mehmet Ali Nahit Sendur, Sercan Aksoy, Emir Charles Roach, Kadri Altundag, and Muhammet Cemal Kizilarslanoglu. 2013. “Trastuzumab Emtansine (T-DM1) for HER2-Positive Breast Cancer.” Current Medical Research and Opinion 29 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e136c770d297110b9612879f80ad3b37&authtype=sso&custid=ns315887.